18:18:08 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-05-22 Ordinarie utdelning SYNT 0.00 SEK
2024-05-21 Kvartalsrapport 2024-Q1
2024-05-21 Årsstämma 2024
2024-02-20 Bokslutskommuniké 2023
2024-02-20 Extra Bolagsstämma 2024
2023-11-10 Kvartalsrapport 2023-Q3
2023-08-22 Kvartalsrapport 2023-Q2
2023-05-24 Ordinarie utdelning SYNT 0.00 SEK
2023-05-23 Årsstämma 2023
2023-05-23 Kvartalsrapport 2023-Q1
2023-02-15 Bokslutskommuniké 2022
2022-11-16 Kvartalsrapport 2022-Q3
2022-08-23 Kvartalsrapport 2022-Q2
2022-05-11 Ordinarie utdelning SYNT 0.00 SEK
2022-05-10 Kvartalsrapport 2022-Q1
2022-05-10 Årsstämma 2022
2022-03-29 Extra Bolagsstämma 2022
2022-02-22 Bokslutskommuniké 2021
2021-11-11 Kvartalsrapport 2021-Q3
2021-07-13 Kvartalsrapport 2021-Q2
2021-05-20 Split SYNT 1:10
2021-05-12 Ordinarie utdelning SYNT 0.00 SEK
2021-05-11 Årsstämma 2021
2021-05-11 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2020-11-12 Kvartalsrapport 2020-Q3
2020-10-02 Ordinarie utdelning SYNT 1.50 SEK
2020-07-14 Kvartalsrapport 2020-Q2
2020-05-05 Kvartalsrapport 2020-Q1
2020-05-05 Årsstämma 2020
2020-02-27 Bokslutskommuniké 2019
2019-11-12 Kvartalsrapport 2019-Q3
2019-07-14 Kvartalsrapport 2019-Q2
2019-04-30 Ordinarie utdelning SYNT 1.50 SEK
2019-04-29 Kvartalsrapport 2019-Q1
2019-04-29 Årsstämma 2019
2019-02-27 Bokslutskommuniké 2018
2018-11-16 Kvartalsrapport 2018-Q3
2018-08-22 Kvartalsrapport 2018-Q2
2018-04-26 Ordinarie utdelning SYNT 0.00 SEK
2018-04-25 Årsstämma 2018
2018-04-25 Kvartalsrapport 2018-Q1
2018-02-21 Bokslutskommuniké 2017
2017-11-10 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-04-26 Ordinarie utdelning SYNT 0.00 SEK
2017-04-25 Årsstämma 2017
2017-04-25 Kvartalsrapport 2017-Q1
2017-02-15 Bokslutskommuniké 2016
2016-10-28 Kvartalsrapport 2016-Q3
2016-08-26 Kvartalsrapport 2016-Q2
2016-04-27 Ordinarie utdelning SYNT 0.00 SEK
2016-04-26 Kvartalsrapport 2016-Q1
2016-04-26 Årsstämma 2016
2016-02-26 Bokslutskommuniké 2015
2015-10-30 Kvartalsrapport 2015-Q3
2015-08-28 Kvartalsrapport 2015-Q2
2015-04-13 Årsstämma 2015
2015-04-13 Kvartalsrapport 2015-Q1
2015-02-17 Ordinarie utdelning SYNT 0.00 SEK
2015-02-13 Bokslutskommuniké 2014
2014-11-28 Kvartalsrapport 2014-Q3
2014-09-26 Extra Bolagsstämma 2014
2014-08-29 Kvartalsrapport 2014-Q2

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
SyntheticMR är ett medicinteknik-bolag som är verksamt inom utveckling av analys - och avbildningsmetoder. Tekniken används huvudsakligen för magnetisk resonanstomografi (MR) inom sjukvården. Tekniken baseras på kvantifieringsbaserad metod som ämnar öka effektiviteten och kvalitén i nuvarande MR-undersökningar. Bolaget etablerades under 2007 och har sitt huvudkontor i Linköping.
2022-02-14 16:54:15

Nemours Children's Health will be integrating SyntheticMR's product SyMRI NEURO at their hospital in Orlando, Florida, to improve scan speed, provide myelin mapping and increase overall clinical efficiency.

Nemours Children's Health is a leader in pediatric care as well as research and clinical trials. Their goal is to prevent and reverse childhood diseases, improve healthcare delivery and keep children safe and healthy for many generations to come. To help answer some of the most pressing questions in children's health, Nemours' Dr. Laura Hayes, will be integrating the SyMRI software into her daily practice. Dr. Hayes is board certified in Diagnostic Radiology and Pediatric Radiology, with additional fellowship training in Pediatric Neuroradiology.

In clinical practice, Dr. Hayes is looking forward to utilizing SyMRI's speed efficiency and myelin mapping. Speed is of major importance in the pediatric field to avoid sedation and ensure that scans can be done quickly, but effectively. Additionally, myelin mapping will be a significant tool as it provides pediatric reference curves to help determine normal myelination, hypo-myelination and more. These reference curves aid the assessment and help save reading time.

"Having a reference for what's normal at this age is key because there is rapid brain development and myelin changes over the early years. You must know what's normal for age and what's not. Baby brains are the hardest scans to read so we need all the tools we can get to help with those," says Dr. Hayes.

SyntheticMR looks forward to providing Dr. Hayes and Nemours Children's with tools to support a more precise diagnosis, reliable monitoring and personalized treatment strategies for her pediatric patients, and to be part of improving pediatric patient care worldwide.

"Having the opportunity to partner with such a well-known pediatric center like Nemours Children's Hospital, Florida really shows the value that SyMRI can bring to those patients that truly need and deserve the best-in-class care.  We believe in the care that Nemours provides and are honored to be part of their mission of restoring and improving the health of children through care and programs not readily available," says Kyle Frye, President Americas & ANZ and CCO of SyntheticMR.